2.1
Benralizumab (Fasenra, AstraZeneca) is indicated 'as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis'.
2 Information about benralizumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for benralizumab.
Price
2.3
Benralizumab costs £1,955 for a solution of 30 mg per 1 ml for injection (excluding VAT; BNF online accessed May 2025).
2.4
The company has a commercial arrangement. This makes benralizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on AstraZeneca's webpage on sustainability.